3', 4'-Dideoxykanamycin Bに関する観察

抄録

Laboratory and clinical investigations were performed on a new antibiotic, 3', 4'-dideoxykanamycin B (abbr. DKB), and following results were obtained.
(1) The minimum inhibitory concentration of DKB was determined on various strains preserved in our laboratory. The values obtained were 0.78-3.13 mcg/ml to Pseudomonas aeruginosa, 0.78-6.25 mcg/ml to Klebsiella, 3.13-6.25 mcg/ml to Proteus, 1.56-6.25 mcg/ml to Escherichia coli, 0.2-0.78 mcg/ml to Staphylococcus aureus, 0.2-12.5 mcg/ml to Pneumococcus, and 25 mcg/ml to Mycobacterium tuberculosis H₃₇Rv-S.
(2) In in vitro experiments with Pseudomonas aeruginosa, Klebsiella pneumoniae and Staphylococcus aureus, DKB demonstrated a slight additive action with cephalothin or penicillin G.
(3) Under the action of DKB, Klebsiella exhibited various degenerations in cytoplasma and cell wall.
(4) DKB was administered to 17 cases of respiratory tract infection at a daily dose of 50 mg×2 for 7-20 days, and the satisfactory results were obtained.